Claudin-18.2 Recombinant Monoclonal Antibody

Claudin-18.2 has emerged as one of the most promising therapeutic targets in oncology, particularly for gastric and pancreatic cancers where this tight junction protein shows highly restricted expression patterns. Unlike the closely related Claudin-18.1 isoform found in normal lung tissue, Claudin-18.2 expression is largely confined to differentiated gastric epithelial cells, making it an attractive target for antibody-based therapies and companion diagnostic development. Researchers investigating this target require antibodies with exceptional isoform specificity to accurately characterize expression patterns and evaluate therapeutic candidates.

This recombinant monoclonal antibody, clone 9C2, offers the consistency and reproducibility that demanding research applications require. Because it is produced from a defined sequence rather than hybridoma culture, you can expect identical performance characteristics across lots, eliminating a common source of experimental variability in long-term studies. The human IgG1 isotype format makes this antibody particularly relevant for researchers developing or characterizing Claudin-18.2-targeted therapeutics.

Validation studies demonstrate the critical isoform specificity researchers need. Flow cytometry analysis shows clear discrimination between Claudin-18.2 and Claudin-18.1, with strong staining of CLDN18.2-transfected KATO3 cells while CLDN18.1-transfected NIH-3T3 cells remain negative. Functional ELISA testing confirms robust binding activity with EC50 values in the low nanogram per milliliter range, indicating high affinity suitable for sensitive detection applications.

Validated for flow cytometry and ELISA with human samples, this antibody supports researchers working in signal transduction, cancer biology, and therapeutic antibody development programs where precise Claudin-18.2 detection is essential for advancing translational research.